drugset
drugset / Trial / NCT05781074

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）

NCT05781074 ↗

Phase 2 Unknown 25 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced biliary tract cancer (BTC).

Timeline

Start
2023-03-23
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

biliary tract cancer